Sonnet BioTherapeutics Holdings, Inc. (SONN) - Dilution Analysis

10-K filing | 0.0M shares outstanding

POS AM filing: Registration Statement No. 333-276250 on Form S-3 relates to the offer and sale of up to $100 million of Common Stock, preferred stock, warrants, debt securities, subscription rights and/or units of the Company, in the aggregate by the Company, as declared effective by the SEC on January 4, 2024

POS AM filing: Registration Statement No. 333-274581 on Form S-1, as amended, relates to the offer and sale of up to 4,016,064 shares of Common Stock, 4,016,064 pre-funded warrants to purchase up to 4,016,064 shares of Common Stock, 8,032,128 warrants to purchase up to 8,032,128 shares of Common Stock, 120,481 underwriter warrants to purchase up to 120,481 shares of Common Stock, 4,016,064 shares of Common Stock issuable upon exercise of the pre-funded warrants, 8,032,128 shares of Common Stock issuable upon exercise of the warrants and 120,481 shares of Common Stock issuable upon exercise of the underwriter warrants, in the aggregate by the Company, as declared effective by the SEC on October 26, 2023.

POS AM filing: Registration Statement No. 333-276250 on Form S-3 relates to the offer and sale of up to $100 million of Common Stock, preferred stock, warrants, debt securities, subscription rights and/or units of the Company, in the aggregate by the Company, as declared effective by the SEC on January 4, 2024

POS AM filing: Registration Statement No. 333-276250 on Form S-3 relates to the offer and sale of up to $100 million of Common Stock, preferred stock, warrants, debt securities, subscription rights and/or units of the Company, in the aggregate by the Company, as declared effective by the SEC on January 4, 2024

POS AM filing: Registration Statement No. 333-274581 on Form S-1, as amended, relates to the offer and sale of various securities of Common Stock, as declared effective by the SEC on October 26, 2023

POS AM filing: Registration Statement No. 333-274581 on Form S-1, as amended, relates to the offer and sale of securities by the Company, as declared effective by the SEC on October 26, 2023.

POS AM filing: Registration Statement No. 333-274581 on Form S-1, as amended, relates to the offer and sale of various securities including shares of Common Stock, pre-funded warrants, and underwriter warrants.

POS AM filing: Registration Statement No. 333-274581 on Form S-1, as amended, relates to the offer and sale of securities by the Company, as declared effective by the SEC on October 26, 2023

POS AM filing: Registration Statement No. 333-276250 on Form S-3 relates to the offer and sale of up to $100 million of Common Stock, preferred stock, warrants, debt securities, subscription rights and/or units of the Company, in the aggregate by the Company, as declared effective by the SEC on January 4, 2024.

POS AM filing: Registration Statement No. 333-276250 on Form S-3 relates to the offer and sale of up to $100 million of Common Stock, preferred stock, warrants, debt securities, subscription rights and/or units of the Company, in the aggregate by the Company, as declared effective by the SEC on January 4, 2024

POS AM filing: Registration Statement No. 333-276250 on Form S-3 relates to the offer and sale of up to $100 million of Common Stock, preferred stock, warrants, debt securities, subscription rights and/or units of the Company, in the aggregate by the Company, as declared effective by the SEC on January 4, 2024

POS AM filing: Registration Statement No. 333-274581 on Form S-1, as amended, relates to the offer and sale of various securities including common stock and warrants.

POS AM filing: Registration Statement No. 333-274581 on Form S-1, as amended, relates to the offer and sale of various securities including common stock and warrants.

POS AM filing: Registration Statement No. 333-274581 on Form S-1, as amended, relates to the offer and sale of securities by the Company, as declared effective by the SEC on October 26, 2023.

POS AM filing: Registration Statement No. 333-274581 on Form S-1, as amended, relates to the offer and sale of up to 4,016,064 shares of Common Stock, 4,016,064 pre-funded warrants to purchase up to 4,016,064 shares of Common Stock, 8,032,128 warrants to purchase up to 8,032,128 shares of Common Stock, 120,481 underwriter warrants to purchase up to 120,481 shares of Common Stock, 4,016,064 shares of Common Stock issuable upon exercise of the pre-funded warrants, 8,032,128 shares of Common Stock issuable upon exercise of the warrants and 120,481 shares of Common Stock issuable upon exercise of the underwriter warrants, in the aggregate by the Company, as declared effective by the SEC on October 26, 2023

POS AM filing: Registration Statement No. 333-274581 on Form S-1, as amended, relates to the offer and sale of various securities including common stock and warrants.

POS AM filing: Registration Statement No. 333-274581 on Form S-1, as amended, relates to the offer and sale of various securities.

10-Q filing | 6.8M shares outstanding

8-K filing: Sonnet BioTherapeutics Holdings, Inc. entered into a Business Combination Agreement with Rorschach I LLC and Hyperliquid Strategies Inc, involving mergers and equity transactions, including PIPE offerings and subscription agreements for shares of Company Common Stock, convertible preferred stock and warrants. ($310.5M proceeds)

8-K filing: Sonnet BioTherapeutics Holdings, Inc. completed a sale of convertible notes and warrants to accredited investors for $2.0 million plus approximately $50,000 additional proceeds from the sale of the Warrants. ($0.05M proceeds)

10-Q filing | 3.2M shares outstanding

10-Q filing | 3.1M shares outstanding

S-1/A filing: This S-1/A filing registers shares of common stock for resale by selling stockholders, including shares issuable upon exercise of warrants.

S-1/A filing: This S-1/A filing registers up to 2,000,000 shares of common stock that may be issued to Chardan Capital Markets LLC pursuant to a committed equity facility, and also registers up to 625,000 shares of common stock that have been or may be issued to Chardan in the Facility pursuant to the Purchase Agreement.

S-1 filing: This S-1 filing registers the resale of common stock and common stock issuable upon exercise of warrants by selling stockholders.

S-1 filing: Sonnet BioTherapeutics Holdings, Inc. files an S-1 to offer up to 2,000,000 shares of common stock through Chardan Capital Markets LLC, as well as up to 625,000 additional shares previously registered on Form S-1 (File No. 333-279095), and may receive up to $25.0 million in aggregate gross proceeds from Chardan under a purchase agreement.

POS AM filing: This POS AM filing relates to the potential offer and sale from time to time by Chardan Capital Markets LLC of up to 625,000 shares of common stock under a committed equity facility.

10-K filing | 3.0M shares outstanding

8-K filing: Sonnet BioTherapeutics Holdings, Inc. entered into securities purchase agreements for a registered direct offering and concurrent private placements, selling shares of common stock, pre-funded warrants, and common warrants for gross proceeds of approximately $3.9 million.

8-K filing: Sonnet BioTherapeutics Holdings, Inc. closed a public offering of 155,000 shares of common stock, pre-funded warrants for 956,111 shares, and warrants for 2,222,222 shares at a combined price of $4.50 per share/warrant and $4.4999 per pre-funded warrant/warrant, resulting in net proceeds of approximately $4.2 million for the company.

S-1/A filing: The company is offering shares of common stock and common warrants to purchase common stock.

S-1/A filing: S-1/A filing for offering of common stock and warrants.

S-1 filing: The company is filing an S-1 to offer common stock, pre-funded warrants, and common warrants. Each share of common stock and pre-funded warrant is being sold together with a common warrant to purchase shares of our common stock.

8-K filing: Stock split 1-for-8 | Outstanding: 5,037,508 → 629,688

10-Q filing | 5.0M shares outstanding

S-3 filing: This prospectus relates to the resale of up to 5,770,140 shares of Sonnet BioTherapeutics Holdings, Inc. common stock issuable upon the exercise of outstanding warrants, including warrants issued to the placement agent, and also relates to an inducement offer letter agreement.

8-K filing: Sonnet BioTherapeutics Holdings, Inc. entered into inducement offer letter agreements with holders of existing warrants to purchase up to 2,828,500 shares of common stock at a reduced exercise price of $1.20 per share, in consideration for the Company's agreement to issue new common stock purchase warrants to purchase an aggregate of 5,657,000 shares of common stock. ($3.4M proceeds)

S-1/A filing: This S-1/A filing relates to the potential offer and sale from time to time by Chardan Capital Markets LLC of up to 5,000,000 shares of common stock pursuant to a ChEF Purchase Agreement.

10-Q filing | 3.1M shares outstanding

S-1 filing: The filing is an S-1 relating to the potential offer and sale from time to time by Chardan Capital Markets LLC of up to 5,000,000 shares of common stock pursuant to a ChEF Purchase Agreement.

10-Q filing | 3.1M shares outstanding

S-3 filing: Sonnet BioTherapeutics Holdings, Inc. is filing an S-3 to offer up to $100,000,000 of common stock, preferred stock, warrants, senior or subordinated debt securities, subscription rights and units.

10-K filing | 3.1M shares outstanding

S-1/A filing: This is an S-1/A filing for offering 4,016,064 shares of common stock, pre-funded warrants to purchase up to 4,016,064 shares of common stock, and common warrants to purchase up to 8,032,128 shares of common stock.

S-1/A filing: The company is offering shares of common stock, pre-funded warrants, common warrants and underwriter warrants.

S-1/A filing: This S-1/A filing relates to an offering of common stock, pre-funded warrants, and common warrants.

S-1 filing: This S-1 filing outlines an offering of common stock, pre-funded warrants, common warrants, and underwriter warrants, with the intention to use net proceeds for research and development, working capital, and general corporate purposes.

8-K filing: Stock split 1-for-22 | Outstanding: 38,511,014 → 1,750,325

10-Q filing | 38.5M shares outstanding

S-1 filing: This prospectus relates to the resale from time to time, by the selling stockholders of up to 5,150,000 shares of common stock they may acquire upon the exercise of outstanding warrants issued in a private placement and up to 150,000 shares of Common Stock that are issuable upon the exercise of certain warrants issued to our placement agent.

8-K filing: Sonnet BioTherapeutics Holdings, Inc. agreed to sell and issue 3,660,000 shares of common stock at $0.45 per share and 1,340,000 pre-funded warrants at $0.4499 per warrant, along with warrants to purchase up to 5,000,000 additional shares, for gross proceeds of approximately $2.25 million. ($2.25M proceeds)

10-Q filing | 27.5M shares outstanding

10-Q filing | 20.2M shares outstanding

8-K filing: Sonnet BioTherapeutics Holdings, Inc. completed a public offering of 11,664,888 shares of common stock and pre-funded warrants to purchase 2,224,000 shares, along with common warrants to purchase 27,777,776 shares, for gross proceeds of approximately $15.0 million. ($12.83M proceeds)

S-1/A filing: Offering of up to 13,888,888 shares of common stock, pre-funded warrants to purchase up to 13,888,888 shares of common stock, and common warrants to purchase up to 27,777,776 shares of common stock.

S-1/A filing: S-1/A filing for offering of common stock, pre-funded warrants, and common warrants.

S-1 filing: The company is offering shares of common stock and common warrants to purchase shares of common stock, as well as pre-funded warrants to certain purchasers.

10-K filing | 7.9M shares outstanding

8-K filing: Sonnet BioTherapeutics Holdings, Inc. sold 2,477,383 shares of its common stock through BTIG under an At-the-Market Sales Agreement for gross proceeds of $6,089,106.90 and filed a prospectus supplement registering the offer and sale of shares of common stock of up to an additional $1,660,000 pursuant to the Sales Agreement. ($6.09M proceeds)

8-K filing: Sonnet BioTherapeutics Holdings, Inc. announced the mandatory conversion of its preferred stock into 552,282 shares of common stock at a conversion price of $4.074 per share, scheduled to occur on or before September 30, 2022.

8-K filing: Stock split 1-for-14 | Outstanding: 60,294,838 → 4,306,774

S-3 filing: This prospectus relates to the resale of up to 11,597,947 shares of Sonnet BioTherapeutics Holdings, Inc. common stock by the selling stockholders.

10-Q filing | 60.6M shares outstanding

8-K filing: Sonnet BioTherapeutics Holdings, Inc. entered into a Securities Purchase Agreement for a private placement of preferred stock and warrants and plans a reverse stock split subject to stockholder approval.

10-Q filing | 60.3M shares outstanding

10-Q filing | 60.3M shares outstanding

10-K filing | 60.3M shares outstanding

8-K filing: Sonnet BioTherapeutics Holdings, Inc. closed a public offering of 33,193,485 shares of common stock and pre-funded warrants to purchase 2,100,632 shares of common stock, along with common warrants to purchase up to 35,294,117 shares, at a price of $0.85 per share and $0.8499 per pre-funded warrant, resulting in gross proceeds of approximately $30.0 million. ($30.0M proceeds)

10-Q filing | 25.0M shares outstanding

S-1/A filing: S-1/A filing for offering of common stock, pre-funded warrants, and common warrants.

S-1/A filing: S-1/A filing for up to 26,785,714 shares of common stock and up to 26,785,714 pre-funded warrants.

S-1 filing: The company is filing an S-1 to offer shares of its common stock and pre-funded warrants to purchase shares of common stock.

8-K filing: Sonnet BioTherapeutics Holdings, Inc. completed the final issuance of shares under its At-the-Market Sales Agreement with BTIG, selling an aggregate of 7,454,238 shares for gross proceeds of $15,874,999. ($15.87M proceeds)

POS AM filing: This prospectus relates to an aggregate of up to 105,812 shares of common stock issuable upon the future exercise of certain outstanding warrants.

10-Q filing | 14.7M shares outstanding

10-Q filing | 17.6M shares outstanding

S-3 filing: This prospectus relates to the resale of up to 11,329,463 shares of common stock issuable upon exercise of outstanding warrants.

S-3 filing: The company is registering for offering and sale from time to time pursuant to Rule 415 under the Securities Act up to $100,000,000 aggregate offering price of common stock, preferred stock, warrants to purchase shares of common stock or preferred stock, debt securities, subscription rights to purchase common stock or debt securities or units composed of any of the foregoing.

10-K filing | 14.7M shares outstanding

10-Q filing | 9.2M shares outstanding

8-K filing: Sonnet BioTherapeutics Holdings, Inc. entered into Warrant Exercise and Omnibus Amendment Agreements with Holders, reducing the exercise price of Series A Warrants to $3.19 per share, and the Holders agreed to exercise all of their Series A Warrants with respect to an aggregate of 3,300,066 shares of Common Stock, expecting to receive aggregate gross proceeds before expenses of approximately $10.5 million. They also amended the Series B warrants to remove a provision and set the number of shares underlying at 4,532,526. ($10.5M proceeds)

S-3/A filing: The filing is an S-3/A form related to a shelf offering of common stock. The prices for the shares will be determined by the prevailing public market price, negotiations, or as described in the plan of distribution.

S-3/A filing: The filing relates to a shelf offering of common stock, with prices determined by the prevailing market or negotiations.

10-Q filing | 0.5M shares outstanding

S-3 filing: The filing relates to a shelf offering of common stock, with the prices to be determined by market conditions, negotiations, or as described in the plan of distribution.

8-K filing: Sonnet BioTherapeutics Holdings, Inc. issued Series A and Series B warrants to investors on April 16, 2020, exercisable for 3,300,066 and 2,247,726 shares of common stock, respectively, following the completion of a business combination and a private placement transaction.

8-K filing: Chanticleer Holdings, Inc. enacted a 1-for-26 reverse stock split, changed its name to Sonnet BioTherapeutics Holdings, Inc., and completed a private placement for $19 million comprised of a credit to Chardan and cash from investors. Series 1 Preferred Units were redeemed and extinguished for $13.50 per unit, and 8% debentures were cancelled. Additionally, Series 2 Preferred Stock were exchanged for shares of preferred stock in Amergent. ($19.0M proceeds)

8-K filing: ChanticleerHoldings, Inc. reduced the exercise price of 382,928 outstanding warrants to $0.50 as an inducement for exercise, with settlement occurring between March 19, 2020 and March 25, 2020.

S-3 filing: Resale of up to 4,149,564 shares of common stock by selling shareholders, including shares issuable upon conversion of Series 2 Convertible Preferred Stock and shares held by certain other stockholders registered on a piggyback basis.

10-K filing | 3.7M shares outstanding

8-K filing: Chanticleer Holdings Inc. completed the sale and issuance of 1,500 shares of Series 2 Convertible Preferred Stock in two tranches for $1,500,000; 1,000 shares on February 11, 2020, and the remaining 500 shares on March 6, 2020. ($1.5M proceeds)

8-K filing: Chanticleer Holdings Inc. sold 1,000 shares of Series 2 Preferred Stock for gross proceeds of $1,000,000 on February 11, 2020, as part of a previously reported Securities Purchase Agreement. ($1.0M proceeds)

8-K filing: Chanticleer entered into a Securities Purchase Agreement for the sale of up to 1,500 shares of a new series of convertible preferred stock with an institutional investor for gross proceeds of up to $1,500,000. ($1.5M proceeds)